| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
|
N Engl J Med
|
2002
|
19.60
|
|
2
|
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.
|
Blood
|
2004
|
11.07
|
|
3
|
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
|
Blood
|
2002
|
8.76
|
|
4
|
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
|
Blood
|
2003
|
4.43
|
|
5
|
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
|
N Engl J Med
|
2007
|
3.97
|
|
6
|
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
|
Lancet
|
2011
|
3.21
|
|
7
|
Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
|
J Clin Oncol
|
2012
|
2.56
|
|
8
|
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
|
J Clin Oncol
|
2007
|
2.35
|
|
9
|
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
|
J Clin Oncol
|
2008
|
2.32
|
|
10
|
Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma.
|
Oncology (Williston Park)
|
2012
|
2.23
|
|
11
|
MALT lymphomas: pathogenesis can drive treatment.
|
Oncology (Williston Park)
|
2011
|
2.20
|
|
12
|
Splenic marginal zone lymphoma: current knowledge and future directions.
|
Oncology (Williston Park)
|
2012
|
2.18
|
|
13
|
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
|
Blood
|
2003
|
2.16
|
|
14
|
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
|
Lancet Oncol
|
2011
|
2.06
|
|
15
|
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
|
Blood
|
2005
|
1.99
|
|
16
|
Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
|
J Clin Oncol
|
2010
|
1.98
|
|
17
|
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
1.98
|
|
18
|
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
|
J Clin Oncol
|
2007
|
1.70
|
|
19
|
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
|
J Clin Oncol
|
2012
|
1.66
|
|
20
|
Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection.
|
Haematologica
|
2005
|
1.65
|
|
21
|
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
|
Clin Lymphoma
|
2002
|
1.61
|
|
22
|
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.
|
Lancet Oncol
|
2009
|
1.60
|
|
23
|
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
|
Blood
|
2012
|
1.58
|
|
24
|
The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma.
|
Blood
|
2009
|
1.57
|
|
25
|
Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2007
|
1.50
|
|
26
|
S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
|
Cell Cycle
|
2010
|
1.45
|
|
27
|
Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study.
|
Leuk Lymphoma
|
2010
|
1.45
|
|
28
|
Pregnancy and multiple myeloma are not antinomic.
|
Leuk Lymphoma
|
2013
|
1.37
|
|
29
|
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
|
Blood
|
2010
|
1.34
|
|
30
|
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
|
J Natl Cancer Inst
|
2011
|
1.34
|
|
31
|
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
|
Blood
|
2006
|
1.32
|
|
32
|
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
|
Haematologica
|
2011
|
1.31
|
|
33
|
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
|
J Clin Oncol
|
2011
|
1.30
|
|
34
|
Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia.
|
Blood
|
2007
|
1.28
|
|
35
|
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
|
J Clin Oncol
|
2014
|
1.26
|
|
36
|
Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation.
|
Biol Cell
|
2009
|
1.24
|
|
37
|
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
|
J Clin Oncol
|
2008
|
1.22
|
|
38
|
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
|
J Clin Oncol
|
2009
|
1.21
|
|
39
|
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.
|
Blood
|
2002
|
1.18
|
|
40
|
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.
|
Blood
|
2009
|
1.16
|
|
41
|
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma.
|
J Hematol Oncol
|
2012
|
1.16
|
|
42
|
Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
|
Haematologica
|
2012
|
1.11
|
|
43
|
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
|
J Clin Oncol
|
2013
|
1.10
|
|
44
|
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.
|
Blood
|
2003
|
1.09
|
|
45
|
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.
|
Eur Cytokine Netw
|
2006
|
1.09
|
|
46
|
Splenic marginal-zone lymphoma: a distinct clinical and pathological entity.
|
Lancet Oncol
|
2003
|
1.08
|
|
47
|
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
|
J Clin Oncol
|
2007
|
1.07
|
|
48
|
Early steps of follicular lymphoma pathogenesis.
|
Adv Immunol
|
2011
|
1.07
|
|
49
|
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
|
J Clin Oncol
|
2002
|
1.03
|
|
50
|
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.
|
Haematologica
|
2013
|
1.03
|
|
51
|
t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma.
|
J Clin Oncol
|
2014
|
1.02
|
|
52
|
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
|
Blood
|
2007
|
1.02
|
|
53
|
Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs.
|
BMC Cancer
|
2011
|
1.02
|
|
54
|
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
|
Haematologica
|
2011
|
1.00
|
|
55
|
CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation.
|
J Biol Chem
|
2010
|
1.00
|
|
56
|
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.
|
PLoS One
|
2012
|
0.99
|
|
57
|
Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.
|
Medicine (Baltimore)
|
2007
|
0.98
|
|
58
|
CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
|
Haematologica
|
2009
|
0.97
|
|
59
|
Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.
|
Genes Chromosomes Cancer
|
2007
|
0.97
|
|
60
|
Transcriptional activation of hTERT, the human telomerase reverse transcriptase, by nuclear factor of activated T cells.
|
J Biol Chem
|
2009
|
0.96
|
|
61
|
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
|
Arch Immunol Ther Exp (Warsz)
|
2010
|
0.94
|
|
62
|
Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
|
Haematologica
|
2007
|
0.94
|
|
63
|
Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas.
|
Blood
|
2006
|
0.94
|
|
64
|
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.
|
Blood
|
2010
|
0.94
|
|
65
|
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
|
Blood
|
2013
|
0.93
|
|
66
|
Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma.
|
Br J Haematol
|
2003
|
0.93
|
|
67
|
Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation.
|
Blood
|
2011
|
0.92
|
|
68
|
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
|
Blood
|
2012
|
0.91
|
|
69
|
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.
|
Blood
|
2013
|
0.90
|
|
70
|
Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
|
Bull Cancer
|
2004
|
0.89
|
|
71
|
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
|
Cancer
|
2009
|
0.89
|
|
72
|
Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
|
Cancer
|
2005
|
0.89
|
|
73
|
Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
|
J Clin Oncol
|
2006
|
0.88
|
|
74
|
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.
|
Haematologica
|
2012
|
0.88
|
|
75
|
CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma.
|
Mod Pathol
|
2011
|
0.86
|
|
76
|
Lentiviral vectors and transduction of human cancer B cells.
|
Blood
|
2010
|
0.86
|
|
77
|
The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
|
Medicine (Baltimore)
|
2014
|
0.85
|
|
78
|
Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001.
|
Leuk Lymphoma
|
2003
|
0.85
|
|
79
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
|
Haematologica
|
2013
|
0.84
|
|
80
|
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
|
Cancer Chemother Pharmacol
|
2007
|
0.84
|
|
81
|
Telomere uncapping during in vitro T-lymphocyte senescence.
|
Aging Cell
|
2008
|
0.84
|
|
82
|
Predictors of prescription errors involving anticancer chemotherapy agents.
|
Eur J Cancer
|
2012
|
0.84
|
|
83
|
Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin's lymphoma.
|
J Neurooncol
|
2008
|
0.84
|
|
84
|
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
|
Blood
|
2008
|
0.83
|
|
85
|
Tumor necrosis factor-alpha mRNA stability in human peripheral blood cells after lipopolysaccharide stimulation.
|
Eur Cytokine Netw
|
2002
|
0.83
|
|
86
|
In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia.
|
Br J Haematol
|
2012
|
0.83
|
|
87
|
µ-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondria-mediated apoptosis.
|
PLoS One
|
2012
|
0.82
|
|
88
|
The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.
|
Haematologica
|
2014
|
0.82
|
|
89
|
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
|
Leuk Lymphoma
|
2014
|
0.82
|
|
90
|
Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases.
|
Histopathology
|
2013
|
0.81
|
|
91
|
Monitoring NK cell activity in patients with hematological malignancies.
|
Oncoimmunology
|
2013
|
0.81
|
|
92
|
Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma.
|
Haematologica
|
2003
|
0.81
|
|
93
|
Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma: a cross-sectional study in Lyon, France.
|
Eur J Gastroenterol Hepatol
|
2004
|
0.80
|
|
94
|
[The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas].
|
Przegl Lek
|
2005
|
0.80
|
|
95
|
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
|
Haematologica
|
2013
|
0.80
|
|
96
|
[The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas].
|
Przegl Lek
|
2005
|
0.80
|
|
97
|
PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.79
|
|
98
|
Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era.
|
Leuk Lymphoma
|
2015
|
0.79
|
|
99
|
Splenic diffuse red pulp small-B cell lymphoma: toward the emergence of a new lymphoma entity.
|
Discov Med
|
2012
|
0.79
|
|
100
|
Obinutuzumab for chronic lymphocytic leukemia.
|
Expert Rev Hematol
|
2014
|
0.79
|
|
101
|
Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma.
|
Ann N Y Acad Sci
|
2005
|
0.79
|
|
102
|
Cytogenetic and molecular analysis of 12 cases of primary cutaneous marginal zone lymphomas.
|
Am J Dermatopathol
|
2006
|
0.79
|
|
103
|
Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
|
Leuk Lymphoma
|
2004
|
0.79
|
|
104
|
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
|
Invest New Drugs
|
2014
|
0.79
|
|
105
|
Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?
|
J Clin Oncol
|
2011
|
0.79
|
|
106
|
[Pathological and clinical correlations in primary cutaneous B-cell lymphomas: a series of 44 cases].
|
Ann Pathol
|
2005
|
0.79
|
|
107
|
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
|
Br J Haematol
|
2013
|
0.78
|
|
108
|
The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell.
|
Haematologica
|
2006
|
0.78
|
|
109
|
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.
|
Cytokine
|
2013
|
0.78
|
|
110
|
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
|
Transfusion
|
2012
|
0.78
|
|
111
|
Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL.
|
Best Pract Res Clin Haematol
|
2011
|
0.77
|
|
112
|
Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
113
|
Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
|
Clin Lymphoma
|
2005
|
0.77
|
|
114
|
Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma.
|
Cancer Genet Cytogenet
|
2007
|
0.77
|
|
115
|
T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
|
Hum Pathol
|
2007
|
0.77
|
|
116
|
Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud.
|
Hematol J
|
2004
|
0.77
|
|
117
|
The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.
|
Curr Hematol Malig Rep
|
2009
|
0.77
|
|
118
|
Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
|
Expert Rev Anticancer Ther
|
2015
|
0.77
|
|
119
|
Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome.
|
Haematologica
|
2007
|
0.77
|
|
120
|
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
|
Blood
|
2014
|
0.77
|
|
121
|
Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease.
|
Eur J Intern Med
|
2005
|
0.76
|
|
122
|
Prognostic systems for lymphomas.
|
Hematol Oncol Clin North Am
|
2008
|
0.76
|
|
123
|
Inherited cytokine response and risk of lymphoma.
|
Lancet Oncol
|
2006
|
0.76
|
|
124
|
The biology of aging and lymphoma: a complex interplay.
|
Curr Oncol Rep
|
2015
|
0.75
|
|
125
|
[Lymphoma classification: a collection for specialists or a medical progress?].
|
Ann Pathol
|
2004
|
0.75
|
|
126
|
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
|
Blood
|
2004
|
0.75
|
|
127
|
Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity?
|
Br J Haematol
|
2010
|
0.75
|
|
128
|
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
|
Anticancer Drugs
|
2016
|
0.75
|
|
129
|
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
|
J Geriatr Oncol
|
2013
|
0.75
|
|
130
|
Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.
|
Nucl Med Commun
|
2017
|
0.75
|
|
131
|
Cat-Scratch Disease: A Pitfall for Lymphoma Evaluation by FDG-PET/CT.
|
Clin Nucl Med
|
2017
|
0.75
|
|
132
|
Comparison study for genotyping of a single-nucleotide polymorphism in the tumor necrosis factor promoter gene.
|
Diagn Mol Pathol
|
2002
|
0.75
|
|
133
|
FDG PET/CT Findings in Abdominal Fat Necrosis After Treatment for Lymphoma.
|
Clin Nucl Med
|
2016
|
0.75
|
|
134
|
Ibrutinib-Induced Lymphocytosis: Cytological Features.
|
Acta Haematol
|
2016
|
0.75
|
|
135
|
Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences.
|
Chemotherapy
|
2014
|
0.75
|
|
136
|
[News in therapeutic management of chronic lymphoid leukemia].
|
Bull Cancer
|
2005
|
0.75
|
|
137
|
Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
138
|
Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma.
|
Clin Nucl Med
|
2016
|
0.75
|
|
139
|
Biomarkers and prognosis in malignant lymphomas.
|
Clin Lymphoma Myeloma
|
2009
|
0.75
|
|
140
|
Maintenance therapy in follicular lymphoma.
|
Curr Opin Oncol
|
2011
|
0.75
|
|
141
|
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
|
Arch Immunol Ther Exp (Warsz)
|
2013
|
0.75
|
|
142
|
Chemotherapy-free treatment in patients with follicular lymphoma.
|
Expert Rev Hematol
|
2015
|
0.75
|
|
143
|
Treatment approaches to asymptomatic follicular lymphoma.
|
Expert Rev Hematol
|
2013
|
0.75
|
|
144
|
[Prognostic factors in lymphomas].
|
Rev Prat
|
2010
|
0.75
|
|
145
|
Atypical cytogenetic presentation of t(11;14) in mantle cell lymphoma.
|
Haematologica
|
2005
|
0.75
|
|
146
|
The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomas.
|
Haematologica
|
2007
|
0.75
|
|
147
|
Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
|
Clin Lymphoma Myeloma
|
2008
|
0.75
|